Excellent Science INNOVATION
Device for measurement of pyroelectric properties of materials
SHARE:
Market Maturity: Exploring
These are innovations that are actively exploring value creation opportunities. Learn more
Market Creation Potential
This innovation was assessed by the JRC’s Market Creation Potential indicator framework as addressing the needs of existing markets and existing customers. Learn more
Go to Market needs
Needs that, if addressed, can increase the chances this innovation gets to (or closer to) the market incude:
  • Prepare for Market entry
  • Secure capital
  • Scale-up market opportunities
Location of Key Innovators developing this innovation
Key Innovators
UNIVERSITAT LINZ
LINZ, AT
Higher Education Institute / Research Centre
The EU-funded Research Project
This innovation was developed under the Horizon 2020 project SensApp with an end date of 31/12/2021
Description of Project SensApp
The detection of biomarkers in body fluids is of great importance for disease early diagnosis. The clinical practice uses typically immunoassay methods (e.g. ELISA, Enzyme-Linked Immuno Sorbent Assay, and related techniques) for biomarker determination. Unfortunately, these techniques fail dramatically in a wide variety of cases where the concentration of biomarkers falls below the limit of detection (LOD). The Alzheimer’s disease (AD) is one real example. Nowadays the AD diagnosis from blood collection is not possible just for the above-mentioned reason. The AD biomarkers are low abundant in blood and they can be determined only in cerebrospinal fluid (CSF), thus requiring a highly invasive intervention on the patient (lumbar puncture) under hospitalization, causing also high costs for the public health. SensApp seeks to develop a bench-top “super-sensor” able to determine low abundant AD biomarkers simply in plasma, from peripheral blood, for very early and non-invasive diagnosis in routine clinical practice. We will develop an outstanding innovative technology that we call droplet split-and-stack (DSS), able to stack the biomarker molecules in sub-microlitre volumes on a solid support before the immunoreactions, thus avoiding diffusion limits and improving significantly the LOD. The super-sensor will be fully automated and cost-effective. An integrated micro-system in polar materials will split the mother drop of the plasma sample in tiny droplets through electric fields and will accumulate them on a microscale site, while an innovative integrated optical system will detect the fluorescence signal directly on the reaction support. SensApp will lay the foundations for a future European industrial leadership involved in all of those clinical studies where the detection of low abundant biomarkers is of vital importance for the welfare of society.

Innnovation Radar's analysis of this innovation is based on data collected on 22/02/2020.